US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo. The double ...
The FDA approved ruxolitinib cream 1.5% (Opzelura) for non-segmental vitiligo in adults and children 12 years and older, making it the only FDA-approved treatment for repigmentation in vitiligo and ...
Emily Kirkpatrick is a former associate style news editor at PEOPLE. She left PEOPLE in 2017. Vesnaandjic / Getty Images Vitiligo is a chronic disorder, often due to genetics or a change in the immune ...
LEATHERHEAD, England--(BUSINESS WIRE)-- Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® ...
Incyte INCY announced that the European Commission (EC) approved the novel cream formulation of JAK1/JAK2 inhibitor ruxolitinib (15 mg/g), Opzelura, for the treatment of non-segmental vitiligo with ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) ...
A condition that causes the skin to lose pigmentation, vitiligo affects around one per cent of the UK population. The long-term disorder, in which white patches of skin appear on different parts of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback